Meeting
2021 ASCO Annual Meeting
Biomarker-oriented study of durvalumab in combination with olaparib and paclitaxel in gastric cancer: A phase 2 trial-in-progress.
Authors
Tae Yong Kim
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
Tae Yong Kim , Jee Sun Yoon , Ah-Rong Nam , Ju-Hee Bang , Kyoung Seok Oh , Hye-Rim Seo , Jae-Min Kim , Do-Youn Oh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03579784
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4153)
DOI
10.1200/JCO.2021.39.15_suppl.TPS4153
Abstract #
TPS4153
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.
First Author: Tae-Yong Kim
Poster
2019 Gastrointestinal Cancers Symposium
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
First Author: Yung-Jue Bang
First Author: B.J. Rimel
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye